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RESEARCH ARTICLE 
Role of survey response rates on valid 
inference: an application to HIV prevalence 
estimates
Miguel Marino1,2*  and Marcello Pagano3
Abstract 
Background: Nationally-representative surveys suggest that females have a higher prevalence of HIV than males in 
most African countries. Unfortunately, these results are made on the basis of surveys with non-ignorable missing data. 
This study evaluates the impact that differential survey nonresponse rates between males and females can have on 
the point estimate of the HIV prevalence ratio of these two classifiers.
Methods: We study 29 Demographic and Health Surveys (DHS) from 2001 to 2010. Instead of employing often used 
multiple imputation models with a Missing at Random assumption that may not hold in this setting, we assess the 
effect of ignoring the information contained in the missing HIV information for males and females through three pro-
posed statistical measures. These measures can be used in settings where the interest is comparing the prevalence of 
a disease between two groups. The proposed measures do not utilize parametric models and can be implemented by 
researchers of any level. They are: (1) an upper bound on the potential bias of the usual practise of using reported HIV 
prevalence estimates that ignore subjects who have missing HIV outcomes. (2) Plausible range intervals to account for 
nonresponses, without any additional parametric modeling assumptions. (3) Prevalence ratio inflation factors to cor-
rect the point estimate of the HIV prevalence ratio, if estimates of nonresponders’ HIV prevalences were known.
Results: In 86% of countries, males have higher upper bounds of HIV prevalence than females, this is consonant with 
males possibly having higher infection rates than females. Additionally, 74% of surveys have a plausible range that 
crosses 1.0, suggesting a plausible equivalence between male and female HIV prevalences.
Conclusions: It is quite reasonable to conclude that there is so much DHS nonresponse in evaluating the HIV status 
question, that existing data is plausibly generated by the situation where the virus is equally distributed between the 
sexes.
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Background
The use of large-scale surveys to estimate local and 
national prevalence of disease, or other population char-
acteristics, typically encounter nonresponse on the sta-
tus of the disease [19]. If the aim of a study is to make 
comparisons of disease prevalence between two groups, 
nonresponse in survey items may introduce bias in the 
comparison, especially if the non-response rate differs 
in the two groups. A variety of methods are available to 
address nonresponse including weighting adjustments to 
account for total nonresponse and imputation methods 
to assign values to missing response items [4]. The devel-
opment of these suite of methods are important because 
accurate national prevalence estimates are needed for 
monitoring the pandemic, policy formulation, planning 
and evaluating treatment interventions.
Consider the motivating example of estimating HIV 
prevalence in African countries. Early published esti-
mates of HIV prevalence for African countries were 
derived from sentinel surveillance which have shown to 
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over—and under—estimate the prevalences when meas-
ured this way [2, 13, 14, 18]. This limitation has led to the 
estimation of HIV prevalence through, presumably more 
accurate, national population-based surveys [27].
The largest national population-based surveys designed 
to estimate HIV prevalence in the developing world are 
the Demographic and Health Surveys (DHS). The DHS 
aim to be a nationally representative, population-based 
set of surveys including HIV prevalence data for multi-
ple countries of Africa, in part because of its use of blood 
collected for HIV testing [5, 9]. One of the claimed major 
advantages of a DHS is that it provides researchers the 
ability to estimate HIV prevalence for the general popu-
lation and for certain subgroups, such as sex and age 
groups.
Throughout Africa, empirical evidence suggests that 
despite large HIV prevalence differences between coun-
tries, females consistently have higher HIV prevalence 
than males [1, 11, 15, 21, 29, 30, 40]. Theories have been 
advanced to explain that the observed sex difference of 
HIV prevalence in Africa is driven by multiple factors 
[25]. Biological differences between males and females 
are thought to explain the sex difference in HIV preva-
lence [10, 31, 32]. It has been observed that younger 
females tend to have older male sexual partners who 
are at higher risk of HIV [16, 17]. Biologically, it is also 
believed that there is higher efficiency of transmission 
from males to females than vice versa [28]. It has also 
been reported that socially, females in African countries 
have less authority in controlling the dynamics of sexual 
behavior [3, 36]. That such a sex differential exists is not 
surprising given the sex differences in the perception of 
health services that have existed [35, 39].
The aim of our study is to evaluate the role of yet 
another factor in the posited observed differences, 
namely nonresponse (refusal to consent to being tested), 
as a potential explanation that could modify the observed 
sex differences in HIV prevalence estimates in 29 DHSs 
from 2001 to 2010. It is common for population-based 
surveys to experience non-ignorable nonresponse on HIV 
relevant variables due to refusal to provide a blood sam-
ple for HIV testing, subject absenteeism, subject mobility 
and general non-consent. Depending on actual reasons 
why subjects fail to provide HIV testing information, sur-
vey nonresponse in the numbers experienced in the DHS, 
cannot be ignored because of the potential to bias esti-
mates of HIV prevalence. We hypothesize that the dif-
ferential nonresponse rates between males and females 
can play a sizable role in the supposed differences of HIV 
prevalence; certainly when the basis for such claimed sex 
differences are the DHS. Several methods to account for 
nonresponse have been proposed including weighting 
adjustments [26], Heckman-type selection models [6], 
mathematical modeling [33] and multiple imputation 
[27]. The most common approach to address this differ-
ential nonresponse issue is to perform multiple imputa-
tions on the missing data [11, 29, 30, 42]. These studies 
conclude that missing subjects typically have higher HIV 
prevalence but the overall effect of nonresponse is neg-
ligible and the observed female to male HIV prevalence 
ratio changes minimally. The biggest limitation of using 
multiple imputation in this setting is that these stud-
ies make a ‘Missing at Random’ (MAR) assumption [23] 
that implies that the HIV status of nonresponders is the 
same as responders with the same observed covariates. 
However, if an unobserved covariate is correlated with 
the decision to get tested and HIV status, this condition 
is violated and multiple imputation would not be a suit-
able method to address this nonresponse issue. In this 
HIV example, this is likely to be the case as individuals 
who suspect or know that they are HIV positive may not 
adhere to being tested. HIV remains a highly stigmatiz-
ing disease in many African countries and subjects may 
decide not to participate in the survey because of a fear 
of discovering their status, or having their status possibly 
revealed and not seeing any advantage in participating in 
the survey [41]. This issue is compounded when the prev-
alence of HIV testing is substantially different between 
males and females [34].
As a companion to multiple imputation when it is not 
appropriate to assume response is MAR, we discuss three 
statistics that are straightforward and intuitive to per-
form to study the sensitivity of inference when there is 
no single accepted class of assumptions about the non-
response mechanism. First, we present an upper bound 
on the potential bias of sex-specific HIV prevalence 
estimates when using only the response data and show 
that this upper bound depends on the amount of nonre-
sponse in males and females. Second, we introduce the 
concept of plausible range to this argument, which stud-
ies the effect of nonresponse on the estimate of the sex 
HIV prevalence ratio without any additional modeling 
assumptions. Finally, we derive an HIV prevalence ratio 
inflation factor that would correct the estimate of the 
HIV prevalence ratio if the nonresponders HIV preva-
lence were known.
Methods
Study population and data
The standard DHSs include information about house 
member demographic characteristics including age and 
sex. Since 2001, a subset of DHSs have included HIV test-
ing results to produce supposed nationally representative 
estimates of HIV prevalence. We study the (first) 29 DHS 
available to us as of writing this paper that performed 
HIV-related measurements.
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We evaluate the sex-specific characteristics of the 
national surveys including the number eligible for HIV 
testing, the HIV testing response rate, the age range, the 
HIV prevalence estimate and the ratio of female to male 
HIV prevalence. HIV prevalence is defined as the num-
ber of subjects with a positive test result for HIV-1 or 
HIV-2 over the number tested for HIV. HIV response 
rate was taken to be the number of subjects with an HIV 
test result over the number eligible for HIV testing. We 
define nonresponse as being eligible for HIV testing and 
having a missing observation on HIV testing which could 
have been due to refusal to be tested, not being available 
during the interview, or any other factor. Our analyses 
apply individual HIV sampling weights that account for 
the DHS sample design [38].
Statistical analysis
To evaluate the impact of missing HIV outcomes on the 
HIV prevalence estimates we present three informative 
quantities, none of which requires any further modeling 
assumptions to be valid. The first measure we present is 
the upper bound on nonresponse bias. Following a simi-
lar framework to that proposed by Cochran [7], let p 
denote the true HIV prevalence for a country. Denote by 
w the proportion of nonresponders in a survey. Associ-
ated with the nonresponders is their HIV prevalence that 
we label pnr. The HIV prevalence of the population, p, 
can be expressed by the following composition formula:
where pr is the prevalence of HIV for the subjects who 
consented to HIV testing (i.e. responders).
Equation (1) identifies how the proportion of the non-
responders in the population plays a role in the estima-
tion of national HIV prevalence. Using this formula, we 
can calculate the bias induced by using the HIV preva-
lence of the fully observed subjects as the true HIV prev-
alence. We have that the bias,
depends on the amount of nonresponse (w) and the dif-
ference in HIV prevalence between the population that 
responds and those who do not respond to the survey. 
Furthermore, because the term |pnr − pr | is between zero 
and one, w provides an upper bound on the bias,
that makes it evident that the difference between the true 
HIV prevalence and the prevalence of the fully-observed 
subjects will be at most the proportion of nonresponses 
in the population. Given that pr is known, a sharper 
bound for the bias is simply
(1)p = pnrw+ pr(1− w)
Bias = w
∣
∣pnr − pr
∣
∣.
(2)Bias ≤ w
when it is assumed that the prevalence of nonresponders 
is larger than that of responders (i.e. pnr > pr).
The second quantity we present is the plausible range. 
Instead of addressing the nonresponse issue through 
scientifically questionable MAR imputation models, we 
propose to focus on the effect this issue has by imple-
menting the metric of plausible range to more honestly 
evaluate the information in the survey. Inspired by the 
work of Cochran et al. [8] we first look at the estimated 
prevalence if we assume all missings were to test nega-
tive. Then the estimated prevalence if all missings were 
to test positive. We construct the HIV prevalence ratio 
plausible range comparing females to males as:
where PR− denotes the estimated HIV prevalence ratio 
when all the missing HIV responses for males and females 
are assigned a negative test result and PR+ denotes the 
estimated HIV prevalence ratio when all nonresponders 
are assigned a positive HIV test result. Formulations for 
PR− and PR+ can be found in the Appendix. The plau-
sible range interval is a measure of how missing HIV 
outcomes potentially affect the point estimate of the sex 
HIV prevalence ratio. A narrow plausible range suggests 
that the effect of nonresponse on the point estimate of 
the prevalence ratio is minimal. Additionally, the location 
of the plausible range interval is important. If the plausi-
ble range interval crosses the null value of 1.0, it is plau-
sible that the HIV prevalence for females is equivalent 
to the HIV prevalence for males even before taking into 
account the standard error of the prevalence ratio. We 
present this statistic as a conservative guide and not as 
a worst-case scenario. Of course the worst-case scenario 
would have all male missings be in the one direction and 
all the female missings be in the other direction, but we 
do not consider this possibility, preferring to believe that 
the reasons for missingness are more likely to be similar 
between the sexes than completely opposite.
The next measure, the prevalence ratio inflation fac-
tor, allows us to quantitate differential sex-behavior. We 
explore the joint role that nonresponse rates and non-
responders HIV prevalence plays on the estimate of 
the sex prevalence ratio. After some algebra (shown in 
the Appendix), the true HIV prevalence ratio between 
females and males (RRadj) adjusting for the HIV charac-
teristics of nonresponders can be expressed as
where RRobs is the observed HIV prevalence ratio 
between females and males, wF is the proportion of 
(3)Bias ≤ w
(
1− pr
)
(4)PR = (PR−,PR+)
(5)RRadj = RRobs ×
[
1+ wF (RF − 1)
1+ wM(RM − 1)
]
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female nonresponders, RF is the ratio of HIV prevalences 
of nonresponders to responders for the female popula-
tion, wM is the proportion of male nonresponders, and 
RM is the ratio of HIV prevalences of nonresponders 
to responders for the male population. The bracketed 
term on the right side Eq. (5) is what we term the preva-
lence ratio inflation factor, which depends on male and 
female nonresponse rates (available from the survey) and 
the HIV prevalence ratio between nonresponders and 
responders (which is unavailable from the survey because 
the HIV prevalence of nonresponders is unknown). If a 
reliable estimate of the HIV prevalence for female and 
male nonresponders could be obtained, then it would 
be possible to adjust the observed prevalence ratio to 
obtain a more representative female to male HIV preva-
lence ratio that accounts for missing HIV outcomes using 
Eq. (5).
Results
Sex-specific observed HIV prevalence estimates and 
nonresponse rates for each of the 29 DHS are presented 
in Table 1. We see a clear pattern of higher reported HIV 
prevalence among females when compared to males. Of 
the 29 DHS analyzed, 26 had an HIV female:male preva-
lence ratio greater than one. The three highest reported 
HIV prevalence ratios among the surveys were in Cote 
d’Ivoire, Senegal and Ethiopia. In these three countries 
the HIV response rates for males (that is, males who 
consented to being tested) were considerably lower than 
most DHS. Across all the DHS analyzed, males had a 
higher HIV nonresponse rate compared to females except 
for the Congo Brazzaville survey. The average HIV test-
ing nonresponse rate across all surveys for females was 
13.4% (range 2.7–29.6%; median: 12.3%) and for males 
20.2% (range: 4.4–36.7%; median: 20.1%).
Upper bound on nonresponse bias
In order to avoid having the older male age groups influ-
ence the results, we restrict the sample to subjects in 
the 15–49 age range. We show bar plots in Fig. 1 of the 
reported HIV prevalence for males and females and their 
HIV prevalence upper bound using Eq.  (3) for 29 DHS 
country surveys. From Fig. 1 we observe that the upper 
bound on the HIV prevalence estimate is dependent 
on the nonresponse rate. As expected, countries with 
high nonresponse rates have a larger upper bound and, 
importantly, this size varies between males and females. 
The bar plots from Fig. 1 identify 25 out of 29 countries 
that have a higher HIV prevalence upper bound for males 
than females, suggesting that it is possible that the HIV 
prevalence ratio can be less than one, reversing the direc-
tion of the observed sex gap in HIV prevalence.
Countries with low observed HIV prevalence esti-
mates typically have higher male HIV upper bounds 
than females. In some instances, the upper bounds on 
HIV prevalence are twice the size for males compared 
to females. For example, Senegal has an observed HIV 
prevalence ratio of 2.07 suggesting that females are twice 
as likely to test HIV positive compared to males. If the 
upper bounds are achieved for males and females in the 
Senegal survey, this would result in an HIV prevalence 
ratio of 0.66, making females 33% less likely to test posi-
tive for HIV than males. Of course, a whole range of ratio 
values between those two extremes is plausible.
We also explore how the HIV prevalence and its upper 
bound vary for males and females across different age 
subgroups. For the 29 DHSs studied, we group country 
surveys into four categories, depending on their HIV 
testing response rates. Within each category, we take the 
weighted average of HIV prevalence and upper bound 
by age group. We plot the weighted average of observed 
HIV prevalence and upper bound across age groups in 
Fig.  2. We see that for surveys with low response rate, 
the observed difference between female and male HIV 
prevalence is large. For surveys with higher response rate 
(> 85%, for example), the observed HIV prevalence differ-
ence is smaller across age groups. Additionally, the upper 
bound of HIV prevalence is consistently higher across 
all age groups in each of the four survey response cate-
gories. A telling finding is that as HIV testing response 
rates increase, the upper bounds for males and females 
HIV prevalences converge (i.e. are equivalent across all 
age groups).
Plausible range
Figure  3 plots the plausible range for 27 DHS (two sur-
veys were excluded because individual sampling weights 
could not be reliably used for nonresponders). From 
Fig.  3, we note that 20 of the 27 surveys (74%) had a 
plausible range that crossed the value of 1.0. With the 
exception of Sao Tome and Principe, the plausible range 
intervals that did not cross the null value had intervals 
that were above 1.0 (Cameroon, Congo Brazzaville, Cote 
d’Ivoire, Lesotho 2009, Rwanda and Swaziland). We also 
note that for every DHS except the Mozambique and 
Rwanda surveys, the point estimate of the HIV preva-
lence ratio is skewed to the right of the plausible range 
interval. This suggests that the prevalence ratio is more 
sensitive to nonresponder’s positive HIV test results. The 
point estimate of HIV prevalence ratio is likely to tend to 
the null if we believe that the nonresponders are mostly 
HIV positive individuals.
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Prevalence ratio inflation factor
An important factor in the estimation of the HIV prev-
alence ratio is the HIV prevalence of female and male 
nonresponders. Equation  (5) can be used to obtain an 
estimate of the true HIV prevalence ratio that accounts 
for sex-specific nonresponse rates and nonresponders 
HIV prevalence. For example, the reported HIV preva-
lence in Zimbabwe for females was 21.1% and for males 
14.6%. The reported HIV prevalence ratio is thus 1.45 
suggesting that females are 45% more likely to have HIV 
than males in 2005–2006. The response rate for females 
(75.9%) was higher than males (63.6%). If the HIV preva-
lence for the 24.1% of females who did not respond and 
the 36.4% of males who did not respond could be esti-
mated, then we could use Eq.  (5) to obtain an adjusted 
HIV prevalence ratio. For the sake of illustration, sup-
pose that the HIV prevalence of nonresponders could be 
estimated and is 25.0% for both males and females. Using 
this information and Eq. (5), we obtain an adjusted HIV 
prevalence ratio:
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The Zimbabwe HIV prevalence ratio changes from 1.45 
to 1.20. This exercise illustrates the importance of obtain-
ing reliable estimates of the subjects who do not consent 
to HIV testing. Unfortunately, we do not know the true 
HIV prevalence of the nonresponders, but we can use 
Eq.  (5) to assess how the HIV prevalence ratio changes 
RRadj = RRobs ×
[
1+ wF (RF − 1)
1+ wM(RM − 1)
]
RRadj = 1.45×
[
1+ 0.241(1.18− 1)
1+ 0.364(1.72− 1)
]
RRadj = 1.20
for different nonresponse HIV prevalences between 
males and females.
Discussion
While biological and social factors continue to play a 
role in the observed difference between male and female 
HIV prevalence in Africa, survey nonresponders has an 
adverse effect on the validity of the inference one can 
draw from such surveys. One can make assumptions, 
usually unverifiable ones, in order to use statistical mod-
els to impute the information. When those assumptions 
are questionable, it is important to consider studying the 
sensitivity of inference to various models for nonresponse 
0
10
20
30
40
Survey response < 80%
Age (years)
Pe
rc
en
t
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●●
●
●
● ●
●
●
0
10
20
30
40
Survey response 80−84.9%
Age (years)
Pe
rc
en
t
●
●
● ● ● ●
●
●
●
●
● ● ●
●
● ● ● ● ●
●
●
●
● ● ● ●
●
Female HIV Prevalence
Female HIV Upper Bound
Male HIV Prevalence
Male HIV Upper Bound
0
10
20
30
40
Survey response 85−89.9%
Age (years)
Pe
rc
en
t
●
●
●
● ●
● ●
● ●
●
●
● ● ●
●
●
●
●
● ● ●
●
●
● ● ● ●
●
0
10
20
30
40
Survey response 90+%
Age (years)
Pe
rc
en
t
15–19 25–29 35–39 45–49 15–19 25–29 35–39 45–49
15–19 25–29 35–39 45–49 15–19 25–29 35–39 45–49
●
●
● ● ● ● ●
● ●
●
● ● ● ●
●
●
●
● ●
● ●
●
●
●
● ●
●
Fig. 2 Line plots of HIV prevalence and the upper bound of HIV prevalence averaged across countries with survey response < 80, 80–84.9, 85–89.9 
and 90+%. Solid red lines are female HIV prevalence estimates, dashed red lines are the female HIV prevalence upper bound. Solid blue lines are 
male HIV prevalence estimates, dashed blue lines are the male HIV prevalence upper bound. Note The upper bound used in these estimations are 
derived from Eq. (3)
Page 8 of 11Marino and Pagano  Emerg Themes Epidemiol  (2018) 15:6 
that do not adopt the Missing at Random assumption. In 
the studies that report the gender difference in HIV prev-
alence [11, 30, 42], sensitivity approaches to the MAR 
assumption such as pattern-mixture models [22] are not 
being reported perhaps because they are complex and 
hard to justify in practice. Alternatively, one can evaluate 
the impact the missing information has on the inference. 
We have chosen the latter, namely to evaluate the impact 
the missing information has on 29 DHSs, focusing on 
the sex-ratio of HIV infected individuals. Our findings 
strongly suggest that the data in these surveys should 
not be the basis for the common belief that the HIV pan-
demic in Africa disproportionately affects females. It is 
quite reasonable to conclude that there is so much non-
response, that existing data is plausibly generated by the 
situation where the virus is equally distributed between 
the sexes.
In general, multiple imputation methods stress the 
importance of studying the sensitivity of inferences to 
various models for nonresponse [37]. Many of the stud-
ies looking at the difference in HIV prevalence between 
males and females fail to perform sensitivity analyses 
looking at multiple imputations assuming Missing Not 
at Random (MNAR). In practice, many researchers find 
the methods to perform sensitivity analyses using MNAR 
multiple imputation (e.g. pattern-mixture modeling) to 
be complex. We have provided an additional approach 
that can be implemented by researchers of any level.
The plausible range we present gives an indication of 
how the point estimate of the prevalence ratio changes 
Fig. 3 Plausible range plot for the HIV prevalence female to male prevalence ratio for 27 DHS. Note The left endpoint of the interval is the plausible 
value of the prevalence ratio if all nonresponders tested positive. The right endpoint of the interval is the plausible prevalence ratio value if all 
nonresponders tested negative. The solid square symbol is the observed prevalence ratio for the particular survey. These intervals only display some 
of the consequences of the missing data. They do not display the sampling uncertainty
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when assigning subjects with an unobservable HIV out-
come to be all positive or all negative. This exercise indi-
cates how much information there is in the data, and how 
robust our conclusions are to the data that are missing. 
Overall, the point estimate of the HIV prevalence ratio 
is skewed to the end of the plausible interval that assigns 
all subjects to be HIV positive, suggesting that the HIV 
prevalence ratio has more flexibility to decrease towards 
the null than to increase away from the null when 
accounting for nonresponders’ HIV status. This interval 
can also be used to evaluate the possibility of the point 
estimate of HIV ratio to be close to or equal to 1.0. About 
three-quarters of DHS surveys had a plausible range that 
crosses 1.0, suggesting a plausible equivalence between 
male and female HIV prevalences for most countries. 
Even among surveys where both males and females 
had a high response rate (> 88%), we observed that half 
of those surveys had a plausible range that crossed 1.0. 
Furthermore, if one were to incorporate the information 
that these numbers result from surveys that are subject to 
sampling variability, wider intervals would result. While 
not all countries show evidence that female and male HIV 
prevalence is equivalent, this exercise shows the variabil-
ity of this possibility across surveys. Lastly, the construc-
tion of the plausible range intervals produce intervals that 
are wider than one would encounter given these large-
scale studies but tighter bounds would require a fabrica-
tion of questionable and tenuous assumptions. Further, 
if we include sampling variability in calculating any sort 
of bounds, such as confidence intervals, for example, we 
would end up with even wider bounds.
Another statistical measure that we present to address 
nonresponse is the prevalence ratio inflation factor. 
This allows an estimate of the HIV prevalence ratio that 
adjusts for differences in HIV prevalence between male 
and female nonresponders to be calculated. Unfortu-
nately, we do not have information on HIV status of 
nonresponders, so it is difficult to know how this group 
behaves, but this ratio can be studied to see the potential 
for change. There have been some studies that show that 
nonresponders behave differently from responders [24]. 
It might be interesting to identify factors that contrast 
the nonresponders from the responders [12] and meth-
ods to estimate the HIV prevalence of nonresponders 
[20] to complete the story. Additional limitations which 
could be addressed by future work include: incorporat-
ing the reason for refusal to provide a blood sample for 
HIV testing and extending these methods to evaluate the 
impact of differential nonresponse on the standard error 
of the point estimate.
Future studies could expand on the plausible range 
interval by considering different endpoints that are not 
all negative test results and not all positive HIV test 
results. For example, one can consider a scenario where 
75% of males and females had an HIV positive test result 
from which new plausible range intervals could be con-
structed. Placing a distribution(s) on this unknown 
parameter would yield credible intervals for the param-
eters of interest. Also, our proposed statistics only evalu-
ated nonresponse for subjects that agreed to interview 
but did not agree to HIV testing. The three proposed sta-
tistics can be applied to the scenario where subjects do 
not agree to interview at all. Lastly, future studies should 
evaluate the robustness of the three measures using sim-
ulated data.
Conclusions
Methods described in this paper evaluate the reported 
sex difference in HIV prevalence from 29 DHSs, without 
the probably unwarranted assumption of “data missing at 
random” to create data not gathered. Our analyses dem-
onstrate the large impact that existing differential HIV 
testing nonresponse between males and females can play 
on HIV prevalences and especially on sex driven preva-
lence ratios in Africa. Indeed, it is of such magnitude that 
one can make a plausibly, qualitatively different conclu-
sion from the data than has been made in the past, when 
the missing data was ignored, or equally as misleading, 
modeled using untenable assumptions.
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Appendix
We define the plausible range to be PR = (PR−,PR+), 
where PR− is the prevalence ratio between females and 
males when all missing observations are assigned a nega-
tive HIV status. If we define the prevalence of the popula-
tion when all female nonresponders have a negative HIV 
outcome as pF−, then we can show
because pFnr is zero. A similar derivation can be produced 
for pM−  (the HIV prevalence when all male nonresponders 
are designated a negative HIV test result). The PR− then 
becomes
where RRobs is the observed sex risk ratio if we ignore the 
missing data. Similarly for PR+, the risk ratio between 
females and males when all missing observations are set 
to positive HIV status is
Now we derive the prevalence ratio inflation factor. We 
show that true HIV prevalence ratio between females and 
males (RRadj) can be expressed as
From (1) we know that the female HIV prevalence can be 
written as
Dividing by pFr  on both sides yields
Defining RF = pFnr/pFr  and rearranging terms, we get
which is equivalent to,
pF− = p
F
r (1− w
F )
PR− =
pF−
pM−
=
pFr (1− w
F )
pMr (1− w
M)
PR− = RRobs ×
(1− wF)
(1− wM)
,
PR+ =
pFr (1− w
F )+ wF
pMr (1− w
M)+ wM
.
RRadj = RRobs ×
[
1+ wF (RF − 1)
1+ wM(RM − 1)
]
.
pF = pFnrw
F + pFr (1− w
F )
pF
pFr
=
pFnr
pFr
wF + (1− wF )
pF
pFr
= 1+ wF(RF − 1),
pF = pFr
[
1+ wF (RF − 1)
]
.
The same calculations yield,
If we define RRadj to be the population HIV prevalence 
ratio comparing females to males, we get
which is equivalent to our claim
where RRobs = pFr /pMr , the HIV prevalence ratio among 
responders.
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